Larimar Therapeutics, Inc.
LRMR
$2.97
$0.113.85%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -95.23M | -80.60M | -64.77M | -58.34M | -45.08M |
| Total Depreciation and Amortization | 326.00K | 318.00K | 322.00K | 324.00K | 313.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.87M | 3.35M | 3.44M | 4.49M | 6.00M |
| Change in Net Operating Assets | 5.15M | 6.18M | 2.72M | 10.58M | 2.45M |
| Cash from Operations | -86.89M | -70.76M | -58.29M | -42.94M | -36.32M |
| Capital Expenditure | -564.00K | -515.00K | -500.00K | -438.00K | -164.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.01M | -84.87M | -106.71M | -180.48M | -127.10M |
| Cash from Investing | -2.58M | -85.39M | -107.21M | -180.92M | -127.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 66.00K | 162.22M | 162.18M | 162.18M | 162.18M |
| Repurchase of Common Stock | -334.00K | -334.00K | -334.00K | -334.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -268.00K | 161.88M | 161.85M | 161.85M | 162.18M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.73M | 5.74M | -3.65M | -62.01M | -1.40M |